I had the honor of interviewing Kenneth Harris, Chief Advisor for CuraSense Advisors about cord blood industry growth rates and trends. There are many misleading metrics being released about the cord blood banking industry, so it was an honor to speak with another person who is extremely knowledgeable about the cord blood banking field. In this interview, we explore growth rates for the global cord blood industry, key trends affecting the industry, differences in geographic opportunities and more. Enjoy. [Read more…]
Exosome Manufacturing: $2.18M Grant Awarded to VivaZome Therapeutics
$2.18m grant awarded to VivaZome Therapeutics for Exosome Therapy; Grant awarded in collaboration with La Trobe University and SeerPharma
18 December 2017, Geelong – Melbourne, Australia: Australian biotech company VivaZome Therapeutics is pleased to announce that it has been awarded an Australian Government CRC-P grant of $2.18m in support of the project “Enabling Exosome Therapy: Developing an Advanced Manufacturing Process”, with the funds provided under the Advanced Manufacturing Scheme.
The Hon Craig Laundy MP (Assistant Minister for Industry, Innovation and Science) oversees the Cooperative Research Centre Projects (CRC-P) Grants Scheme which supports the development of innovative Australian companies and sectors.
Joining VivaZome in the CRC-P are La Trobe University and SeerPharma Pty Ltd, each of which bring high-level scientific and operational skills to the 3 –year project. VivaZome will also engage with the CSIRO to provide expertise in industrial–scale manufacturing. [Read more…]
ArunA Biomedical Launches Exosome Biologics to Treat CNS and Neurodegenerative Disorders
Company rapidly moving toward clinical development of cell-free biologic therapy as study published in Translational Stroke Research demonstrates human neural exosomes improve tissue and functional recovery in pre-clinical model
January 03, 2018 08:00AM, ATHENS, Ga. — ArunA Biomedical announces the official launch of a new class of cell-free exosome biologics to treat central nervous system and neurodegenerative disorders. With an initial focus on an exosome therapeutic for stroke, the company published results of a study today in Translational Stroke Research that found extracellular vesicles (EVs) derived from human neural stem cells improved tissue and functional recovery in murine thromboembolic stroke models.
The study was led by Dr. Steven Stice, a Georgia Research Alliance Eminent Scholar endowed chair, Professor and Director of the Regenerative Bioscience Center at The University of Georgia and who serves as Co-Founder, Chief Executive and Chief Scientific Officer for ArunA Biomedical. The study was conducted in collaboration with Dr. Nasrul Hoda at Augusta University. [Read more…]
Current and Future Opportunities for Stem Cell Exosomes
To operate successfully within the exosome marketplace, it is vital to assess novel opportunities for product development. Currently, there are five market segments that compose the market for stem cell exosomes. These market segments include: Exosome therapeutics, diagnostic tools, research tools, cosmeceuticals, and manufacturing technologies. [Read more…]
GenCure Opens BioManufacturing Center for cGMP Production of Human MSCs
Biologics development and manufacturing organization supports transfer of laboratory research from preclinical evaluation through clinical trials and commercialization
- « Previous Page
- 1
- …
- 197
- 198
- 199
- 200
- 201
- …
- 314
- Next Page »